Defining the Skin and Blood Biomarkers of Ichthyosis
Part of paid clinical trials in Chicago, Illinois.
- Sponsor
- Northwestern University
- Study ID
- NCT03417856
- Status
- Enrolling By Invitation
Conditions
- Ichthyosis
- Netherton Syndrome
Eligibility Criteria
- Sex
- ALL
- Age
- 1 Year - 60 Years
- Healthy Volunteers
- Accepted
Study Details
Ichthyosis is a group of genetic skin disorders that present with dry, thickened, scaly, or flaky skin. As of today, there is no cure or treatment. Doctors can only treat the dry skin with different types of emollients to soften the scale. A deeper understanding of this disease is required to develop better treatments. There are different types of cells and cell-produced signals (biomarkers) that are being studied in order to help find these new treatments. Looking at biomarkers has been successful in helping us to understand other skin disorders better. The purpose of this study is to determine which blood and skin biomarkers characterize ichthyosis. Hypothesis: We predict that the biomarkers correlating with disease activity in Netherton syndrome will be different than the biomarkers found to correlate with the lamellar and other ichthyosis phenotype.
Key Dates
- Start date
- Jan 31, 2018
- Status verified
- Apr 2026
- Primary completion
- Dec 31, 2027
- Completion
- Dec 31, 2027
Study Design
- Enrollment
- 200 participants (estimated)
Arms
- Arm: ControlHealthy subjects with no history of ichthyosis from 1 year to 60 years of age.
- Arm: IchthyosisSubjects with a diagnosis of Netherton syndrome or ichthyosis from 1 year to 60 years of age.
Primary Outcome Measure
Cellular infiltrates [ Time Frame: One year ]
Locations (4)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Ann & Robert H. Lurie Children's Hospital of Chicago | Chicago | Illinois | 60611 | - |
| Northbrook Lurie Children's Outpatient Clinic | Chicago | Illinois | 60611 | - |
| Northwestern University | Chicago | Illinois | 60611 | - |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | - |
Find similar trials in Chicago, IL
Related Studies
- A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725PHASE1 · Recruiting · BioCryst Pharmaceuticals · Palo Alto, California
- Clinical Study of QRX003 Lotion in Subjects With Netherton SyndromePHASE2/PHASE3 · Recruiting · Quoin Pharmaceuticals · Chicago, Illinois
- Thera-Clean® Microbubbles System in Patients With Skin DiseasesEARLY_PHASE1 · Enrolling By Invitation · Northwestern University · Chicago, Illinois
- Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton SyndromePHASE2/PHASE3 · Recruiting · Quoin Pharmaceuticals · San Diego, California